“I think this really now suggests that Rezum is a financially viable procedure across these different treatment settings…the reimbursement now is really quite favorable,” says David M. Albala, MD.
In this video, David M. Albala, MD, discusses the recent change made by the Centers for Medicare & Medicaid Services regarding Rezum water vapor therapy. This new change allows for more financial coverage for patients with benign prostatic hyperplasia (BPH) who seek this treatment. Albala is a urologist at Associate Medical Professionals and chief of urology at Crouse Hospital in Syracuse, New York.
Private equity acquisition is linked with lower MIPS scores for urologists
October 23rd 2023“As private equity firms increasingly engage in urology, key stakeholders, including policymakers and urologists, need to ensure that the quality of care is not compromised with the structural changes implemented after acquisition," write the authors.
2 Clarke Drive
Cranbury, NJ 08512